OncoMatch/Clinical Trials/NCT02961101
Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies
Is NCT02961101 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Anti-PD-1 antibody and Decitabine for malignancies multiple.
Treatment: Anti-PD-1 antibody · Decitabine · Chemotherapy — The purpose of this study is to assess the feasibility, safety, and efficacy of anti-PD-1 antibody alone or in combination with low-dose decitabine in patients with relapsed or refractory malignancies, including Non-Hodgkin'lymphoma, Hodgkin'lymphoma, gastrointestinal cancers, hepatocellular carcinoma, breast cancer, ovarian cancer or lung cancer or renal-cell cancer or pancreatic cancer or bile duct cancer.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1,000/μL; Platelet count ≥ 70,000/µL
Kidney function
Serum creatinine ≤ 1.5 x ULN
Liver function
Serum bilirubin level ≤ 1.5 x ULN; ALT/AST ≤ 2.5 x ULN
Cardiac function
adequate heart function
adequate bone marrow, live, renal, lung and heart functions. Absolute neutrophil count ≥ 1,000/μL. Platelet count ≥ 70,000/µL. Serum bilirubin level ≤ 1.5 x ULN. Serum creatinine ≤ 1.5 x ULN. ALT and AST ≤ 2.5 x ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify